A new generation of

Immunotherapy

A recipient of FDA's Fast Track designation, Diakonos is a clinical-stage biotechnology company developing a groundbreaking Dendritic Cell Vaccine (DCV) for difficult-to-treat cancers.

Learn More

Redefining the Potential of Immunotherapy

Dentritic
Cell Vaccines

Developed at the Texas Medical Center, DOC1021 represents a novel approach to fighting cancer that harnesses the body’s natural anti-viral immune response.

At the core of DOC1021 is Diakonos’ proprietary “double-loading” technique. This patented process tricks the body into perceiving cancer cells as virally infected cells, mirroring the natural detection and elimination process for viral infections.

Learn More

Powered by a

Groundbreaking
Discovery on the
Immune System

DOC1021 is based on a discovery on how dendritic cells are able to detect and respond to viral threats. Based on Diakonos’ research, it is now known that dendritic cells compare antigens presented on MHC Class 1 and 2.

When identical antigens are detected on both MHC Class 1 and 2, dendritic cells mobilize formidable CD8 CD161 T cells to destroy what the immune system believes are infected cells throughout the body.

Learn More About Our Research

Diakonos Oncology

News & Media

Neurosurgeon Joseph Georges, P.I. for Diakonos Oncology’s Phase 1 Trial of Its Unique Dendritic Cell Vaccine for Gliobastoma, Receives the CNS 2024 Rosenblum-Mahaley Clinical Research Award

The Congress of Neurological Surgeons (CNS) award, presented at its annual meeting September 28 – October 2, 2024, is given to the best clinical paper with special recognition for innovative treatment approaches that improve patient outcomes. Dr. Georges was honored for his analysis of the positive results of Diakonos’ Phase 1 trial of its highly […]

CNS 2024 Conference Presentation: Diakonos Oncology’s Autologous Dendritic Cell Vaccine (DOC1021) Yields 93% 12-Month Survival for Glioblastoma Patients

The data were presented during the Congress of Neurological Surgeons Meeting, September 28 – October 2, 2024, in Houston, TX. Early analysis of the results shows no dose-limiting toxicities or concerning SAEs, and 14 of 15 evaluable patients were alive at 12 months. A Phase 2 trial of DOC1021 is expected to be initiated in […]

<em>Innovation Map Houston</em> – Houston Oncology Therapeutics Company Raises 11.4M in Seed Funding

Innovation Map Houston – Houston Oncology Therapeutics Company Raises 11.4M in Seed Funding

Clinical Trials

Underway

Discover our treatment centers and find out which one is best for you.

Pancreatic Adenocarcinoma

Baylor College of MedicinePhase 1, NCT04157127

Conducted in partnership with the Baylor College of Medicine, this phase 1, first in man trial is to determine the safety, toxicity, and feasibility of delivering autologous Dendritic Cells (DCs) to Pancreatic Cancer patients as adjuvant therapy following completion of standard chemotherapy.

MD Anderson Cooper, UT Health Science Center<br /> Phase 1, NCT04552886

Glioblastoma

MD Anderson Cooper, UT Health Science Center
Phase 1, NCT04552886

Conducted in partnership with the MD Anderson Cooper Hospital, this is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a Diakonos loaded Dendritic Cell Vaccine in nine to twenty-four adult patients diagnosed with Glioblastoma (GBM) after undergoing neurosurgical tumor resection, and in whom a neuropathological diagnosis has been established.

Sarcoma

MD Anderson
Phase 1, Pending

Conducted in partnership with the MD Anderson, this is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a Diakonos loaded Dendritic Cell Vaccine in nine to twenty-four adult patients diagnosed with Sarcoma after undergoing Standard of Care.

Serving the Patient,
not the Cancer.

Expanded Access Program